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Reductive DNA damageBased on a molecular-mechanism-based anticancer drug discovery program enabled by an innovative
femtomedicine approach, we have found a previously unknown class of non-platinum-based halogenated mol-
ecules (called FMD compounds) as potent antitumor agents for effective treatment of cancers. Here, we present
in vitro and in vivo studies of the compounds for targeted chemotherapy of cervical, breast, ovarian, and lung can-
cers. Our results show that these FMD agents led to DNA damage, cell cycle arrest in the S phase, and apoptosis in
cancer cells. We also observed that such a FMD compound caused an increase of reduced glutathione (GSH, an
endogenous antioxidant) levels in human normal cells, while it largely depleted GSH in cancer cells. We corre-
spondingly found that these FMD agents exhibited no or little toxicity toward normal cells/tissues, while causing
signiﬁcant cytotoxicity against cancer cells, aswell as suppression and delay in tumor growth inmouse xenograft
models of cervical, ovarian, breast and lung cancers. These compounds are therefore a previously undiscovered
class of potent antitumor agents that can be translated into clinical trials for natural targeted chemotherapy of
multiple cancers.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The conquest of cancer continues to pose great challenges tomedical
science (Reese, 1995; Varmus, 2006; Alberts, 2011; Watson, 2013).
There is a compelling need for innovative cancer research integrating
biomedical sciences with new technology in order to ultimately con-
quer cancer. Femtosecond (fs) (1 fs = 10−15 s) time-resolved laser
spectroscopy (fs-TRLS) is a direct technique to visualizemolecular reac-
tions in real time. Its application to chemical and biological systems gave
birth to the ﬁelds of femtochemistry and femtobiology, with the
pioneering contribution of Zewail (2000). Further, femtomedicine
(FMD), which fuses ultrafast laser spectroscopic techniques with bio-
medical sciences, was recently coined to advance fundamental under-
standing and therapies of human diseases notably cancer (Wang et al.,
2009; Lu, 2010a; Nguyen et al., 2011).
In particular, we proposed that dissociative-electron-transfer (DET)
reactions may be exploited to improve cancer therapy (Lu, 2010a; Luo
et al., 2012). Prior to our studies in FMD, it had strikingly been found
that electron-induced dissociation of halogenated molecules wereand Astronomy, University of
, Canada.
. This is an open access article underenhanced by up to 30,000 times with the presence of polar molecules
such as NH3 and H2O, and a DET mechanism involving a prehydrated
electron (epre− ) trapped in polar media was proposed to explain the re-
sults (Lu and Madey, 1999; Lu, 2010b). Employing fs-TRLS, we demon-
strated that epre− in liquid water has a lifetime of about 500 fs and is a
weakly-bound excited state of the hydrated/solvated electron (Wang
et al., 2008).We further discovered that the epre− plays a key role in caus-
ing the biological effects of ionizing radiation: its ultrafast DET reaction
leads to chemical bond breaks at the guanine base (Wang et al., 2009)
and strand breaks in DNA (Nguyen et al., 2011). Our ﬁndings challenged
the conventional notion that damage to the genome by ionizing radia-
tion ismainly oxidative, induced by oxidizingOH•, andmight lead to im-
proved strategies for radiotherapy of cancer (Lu, 2010a).
We have also discovered the DET mechanism of cisplatin (Lu, 2007;
Lu et al., 2007). Platinum compounds as a class of antitumor agents
were discovered unexpectedly by the biophysicist Rosenberg et al.
(1965, 1969). Despite its severe toxicity (Reese, 1995), cisplatin is a
widely-used drug in the treatment of a variety of cancer, including ovar-
ian, testicular, cervical, bladder, lung, head and neck, lymphomas, and
brain cancers, both as chemotherapy alone and in combination with ra-
diotherapy. Although platinum compounds are well-known DNA-
attacking agents, their precisemolecularmechanismof action remained
elusive until recently. Through fs-TRLS studies, we found that cisplatin isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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as an ultrashort-lived epre− produced by radiolysis of water (Lu, 2007):
epre
− þ Pt NH3ð Þ2Cl2→ Pt NH3ð Þ2Cl2
 −→Cl− þ Pt NH3ð Þ2Cl•
epre
− þ Pt NH3ð Þ2Cl→ Pt NH3ð Þ2Cl2
 −→Cl− þ Pt NH3ð Þ2•:
ð1Þ
The resultant cis-Pt(NH3)2Cl• and cis-Pt(NH3)2• radicals are highly ef-
fectively in inducing DNA strand breaks. For cisplatin as a chemothera-
peutic drug, its DET reaction with the G base in DNA was also observed
(Lu et al., 2007). This DET mechanism has directly unraveled the
radiosensitizing effect of cisplatin (Lu, 2007) and the long-existingmys-
terywhy the cisplatin-like drugs result in the preferential binding of the
cis-Pt(NH3)2 to two neighboring G bases in DNA (Lu et al., 2007). Other
researchers have subsequently conﬁrmed this DET mechanism in
experiments and theoretical calculations (Kopyra et al., 2009;
Kuduk-Jaworska et al., 2011).
Similarly, we also found an ultrafast DET mechanism for a
halopyrimidine family (XdUs, X = I, Br and Cl) as potential sensitizers
for radiotherapy (Wang et al., 2006; Wang and Lu, 2007, 2010). Using
fs-TRLS, we observed directly the ultrafast DET reactions of XdUs with
epre− , leading to the formation of the reactive radical (dU•), but they are
far less efﬁcient than that of cisplatin, due to the lack of the NH3 groups
as the effective electron-transfer promoter (Lu and Madey, 1999; Lu,
2010b), and thus have not sufﬁcient radiosensitizing efﬁcacies.
Our studies in FMD have led to the discovery of a reductive damaging
mechanism in DNA (Wang et al, 2009; Lu, 2010a; Nguyen et al., 2011).
More recently, we further demonstrated the reductive damaging mecha-
nism inhuman lung and skin normal cells, which causes serious reductive
DNA damage and genetic mutations andmight be related to the patholo-
gy of diseases, especially cancer (Lu et al., 2013). We observed contrast
differences in effects of an antioxidant (EGCG) on human normal and ab-
normal (cancer) cells: It caused DNA damage, mutations and cell death
more effectively in normal cells than cancer cells. Our results provided a
compelling explanation for the conﬁrmed observation in clinical trials
that increases of some cancers such as lung and skin cancers are associat-
ed with antioxidants (The ATBC, 1994; Albanes et al., 1996; Omenn et al.,
1996). DeNicola et al. (2011) also recently showed evidence in mice that
several oncogenes actively induce transcription of Nrf2 — the transcrip-
tion factor that mainly regulates physiological antioxidant pathways —
that is required for tumor initiation. This Nrf2 antioxidant pathway may
therefore lead to a more reduced intracellular environment that enables
tumor initiation, though its link to a promotion effect of antioxidant sup-
plementation on human tumorigenesis has been questioned (e.g., Perera
and Bardeesy, 2011). Moreover, researchers have also reviewed that the
resistance or incurability of (later-stage) metastatic cancers are related
to higher-level endogenous antioxidants (e.g., glutathione) in a variety
of types of tumor cells/tissues (Calvert et al., 1998; Estrela et al., 2006;
Traverso et al., 2013;Watson, 2013). Our ﬁnding of a reductive damaging
mechanism may lead to effective prevention and therapies.
Our mechanistic studies in FMD, described above, have now led to
the discovery of a previously unknown class of non-platinum-based
compounds, which essentially act as cisplatin analogues. Some general
features of these compounds are that they comprise an aromatic ring
(rather than a platinum coordinating ion), coupled to two NH2 groups
as the electron transfer promoter and one or more halogen atoms (Cl,
Br or I), such as 4,5-dichloro/dibromo/diiodo-1,2-diaminobenzene
(benzenediamine/phenylenediamine) and 4(3)-chloro/bromo/iodo-
1,2-diaminobenzene (benzenediamine/phenylenediamine) (shortened
as FMD-nX-DABs or B(NH2)2Xn with X = Cl, Br or I, and n = 1, 2).
Their structures are shown in Fig. S1 in Supplementary information.
We have observed that such FMD compounds are highly effective in
DET reaction with weakly-bound electrons (unpublished data; Wang
et al.), whichmay be either intrinsically rich in tumor cells/tissues or ex-
ogenously produced by ionizing radiation of biological systems. The re-
sultant radical [B(NH2)2Xn-1]• can effectively lead to DNA damage andcell death. An advantage of these FMD agents over XdUs and cisplatin
is that FMDs are effective in a DET reaction but are far less toxic due to
the absence of the heavy metal (Pt). It has been shown that the
cisplatin-induced nephrotoxicity is mainly due to the binding of Pt to
proteins in kidneys of cisplatin-treated mice (Townsend and Hanigan,
2002; Zhang et al., 2006). It is the severe toxicity of Pt that led to the
call to terminate the attempt to develop new Pt-based anticancer
drugs (Reese, 1995). Thus, such non-Pt-based FMD compounds (FMD-
nX-DABs) are highly desirable anticancer agents. This study presents
in vitro and in vivo results of FMDs as translatable antitumor agents
for natural targeted chemotherapy of cervical, breast, ovarian, and
lung cancers with minimal toxicity.
2. Methods
Details for cell lines and culture conditions, cell viability assays, DNA
DSB assays, apoptosis assays, and cell cycle analysis have been published
previously (Luo et al., 2012; Lu et al., 2013). Only brief descriptions and
different details are given here. ME-180 and MDA-MB-231 cells were
cultured with the ATCC-formulated McCoy's 5A medium supplemented
with 10% FBS, and L-15 Medium (Leibovitz) with 10% FBS, respectively.
All the cells were maintained at 37 °C in a humidiﬁed atmosphere con-
taining 5% CO2, except for MDA-MB-231 cells maintained at no CO2 (ac-
cording to ATCC's instruction). The cell growth and survival rates with
various treatments were measured by the 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazoliumbromide (MTT) assay (Invitrogen). DNA
double-strand breaks (DSBs) were measured by detection of the phos-
phorylated H2AX foci using the HCS DNA Damage Kit (Invitrogen). The
images of cells were acquired with a Nikon Eclipse TS100 ﬂuorescence
microscope; quantitative analyses of activated γ-H2AX (DNA DBS
yield) in the cells were performed using an Image J software. The
CellEvent™ Caspase-3/7 Green Detection Kit (Invitrogen) was used for
the detection of activated caspases and apoptotic cells using ﬂuores-
cence microscope, following the vendor's protocol, as described previ-
ously, while DNA fragmentation and cell cycle analysis were measured
by ﬂow cytometry using a standard APO-BrdU™ TUNEL assay kit
(Invitrogen) (Luo et al., 2012). For the latter, the data were analyzed
using a FlowJo software for quantitative measurements of apoptotic
cells. The DNA histograms were also used for cell cycle analysis. The
ﬁts to the DNA histograms of the samples were performed by the Wat-
son model to achieve a lowest RMS (root mean squared) score.
To show the reactivity of our FMD agents with antioxidants in human
normal and cancer cells, we measured the intracellular reduced glutathi-
one (GSH) levels of both humannormal cells (GM05757) andhuman cer-
vical cancer cells (ME-180) in control (with no FMDs) and treated by
various concentrations of an exemplary FMD compound (FMD-2Br-
DAB) using a GSH detection kit (Abcam), following the manufacturer's
protocol. Brieﬂy, 2 × 105 GM05757/ME-180 cells were plated into T25
ﬂasks in 8 ml of MEM/McCoy's 5A with 10% FBS and were cultured over-
night at 37 °C before the addition of the test FMD compound (0, 50, and
100 μM). Cellswere incubatedwith the compound for 24h, andwerehar-
vested and washed with PBS. For all samples, the cells were counted and
lysed by 5%metaphosphoric acid at the concentration 8×105 cells/100 μl.
The cell lysates were centrifuged at 12,000 rpm for 5 min and superna-
tants were collected and diluted using the assay buffer by 10 times for
our experiments. TheGSH levelsweredetectedwith a 96-wellﬂuoromet-
ric microplate reader for an excitation wavelength at 485 nm and emis-
sion wavelength at 538 nm, which were close to the ex/em = 490 nm/
520 nm suggested by the manufacturer.
To derive the mouse xenograft models of ME-180 cervical cancer,
A549 lung cancer, MDA-MB-231 breast cancer and NIH:OVCAR-3 ovar-
ian cancer for in vivo growth delay studies involving a FMD compound,
6–8 week old female SCID mice were injected s.c. in the ﬂank with
1.5 × 106 ME-180 cells or 5 × 106 A549/MDA-MB-231/NIH:OVCAR-3
cells. The treatments were started when xenografts reached a volume
of 100–150 mm3. For each treatment, mice were allocated in complete
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Fig. 1. In vitro toxicity assays of FMD compounds (FMD-nX-DABs) versus cisplatin. Cell viabilities of human normal cells (GM05757 andMRC-5) after 72-hr treatment of cisplatin or FMD
compounds at various concentrations, where the clinically used chemotherapeutic drug and radiosensitizer cisplatin was used as a reference. The cell viability was measured byMTT. A:
GM05757 normal cells treated by cisplatin, showing an IC50 value of ~10 μM. B: GM05757 normal cells treated by FMD compounds, showing an IC50 value over 200 μM. C:MRC-5 normal
cells treated by cisplatin, showing an IC50 value of ~6 μM. D: MRC-5 normal cells treated by FMD compounds, showing an IC50 value over 200 μM.
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FMD); (2) FMD-2Br-DAB at 7mg/kg or FMD-2I-DAB at 5mg/kgwas ad-
ministrated for totally 5/10 IP injections at each other day. Mice were
weighed, and ﬂank tumors were measured every 2–5 days with cali-
pers, and tumor volumes were calculated. Growth delay was calculated
as the time difference (in days) between treatment and control groups
to grow to 500 mm3.
For acute toxicity assay, liver and kidney toxicity biomarkers were
measured through proteins, enzymes, metabolites, and electrolytes.
Blood samples were collected by a terminal cardiac puncture of the
mice at the end of the treatment with 0 and 7 mg/kg FMD-2Br-DAB or
5 mg/kg FMD-2I-DAB daily for 10 days. Analyses of blood serum sam-
ples were provided by the Animal Health Laboratory of the University
of Guelph. Moreover, mice were observed for any physical toxicity.
These physical indicators included: body weight changes, dull sunken
eyes, rapid/shallow breathing, hunched back, and lethargy.
Wax-embedded tumor tissue samples from SCIDmice in the control
group and treatment groups (FMD-2Br-DAB at 7 mg/kg × 5; FMD-2I-
DAB at 5 mg/kg × 5) were obtained at 24 h post-treatment and sec-
tioned at 4 μmonto polarized slides for colorimetric TUNEL assay. To vi-
sualize and quantify apoptotic cells in tumor tissue, TUNEL assay was
performed using the DeadEnd™ Colorimetric TUNEL System (Promega,
Madison, WI, USA) according to the manufacturer's protocol. Apoptotic
cells were visualized by staining them in brown color. Nuclei were
counterstained using Harris-modiﬁed hematoxylin, and slides were
mounted. Percentage of apoptotic cells is expressed as a percentage of
total cells in the measured regime.
All the animal experiments were conducted in compliance with the
Animals for ResearchAct of Ontario, the Guide to the Care andUse of Ex-
perimental Animals from the Canadian Council on Animal Care and theUniversity of Waterloo's Guidelines for the Care and Use of Animals in
Research and Teaching (AUPP No. 13-30).
Data are presented as mean value ± SEM, and statistically analyzed
with two-tailed and paired t-tests. A P value b 0.05 was considered sta-
tistically signiﬁcant (P* b 0.05; **P b 0.01; ***P b 0.001).
3. Results
3.1. In Vitro Toxicity Tests of FMD-nX-DABs vs Cisplatin
The in vitro toxicity of FMD-nX-DABs versus cisplatin was investi-
gated in human skin normal cells (GM05757) and lung normal cells
(MRC-5), which are sensitive to the toxicity of exogenous chemicals
(Lu et al., 2013). The cells were incubated with each of the agents for
72 h, and then the cell viability was measured by MTT assay, one of
the most commonly used cell viability assays. As shown in Fig. 1A and
C, the normal cells were effectively killed by cisplatin in a dose-
dependent manner with measured IC50 values of about 10 and 6 μM
(at which the cell survival rate is 50% with respect to untreated cells)
for GM05757 and MRC-5 normal cells, respectively. This conﬁrms that
cisplatin is indeed a highly toxic drug. In contrast, the data plotted in
Fig. 1B and D show that the treatment of FMD compounds led to little
toxicity toward human normal cells with measured IC50 values of
≥200 μM (except IC50 = 150 μM for FMD-2I-DAB on MRC-5 cells),
which were more than 20 times the IC50s of cisplatin.
3.2. In Vitro Anti-Cancer Effect Tests of FMD-nX-DABs vs Cisplatin
The in vitro anti-tumor effects of FMDagents vs cisplatinwere inves-
tigated in human cervical cancer (HeLa or ME-180), breast cancer
547Q.-B. Lu et al. / EBioMedicine 2 (2015) 544–553(MDA-MB-231), lung cancer (A549) cell lines and the cisplatin-
resistant human ovarian cancer (NIH:OVCAR-3, HTB-161) cell line. As
shown in Fig. 2A–D, these FMD agents effectively killed various cancer
cells in a dose-dependent manner at 0–200 (250) μM. As also shown
in Table S1, the FMD compounds had IC50 values far below 200 μM
against HeLa, ME-180, MDA-MB-231, A549 and NIH:OVCAR-3 cancer
cells for the 72-hr treatment. In particular, cervical cancer (ME-180)
and lung cancer (A549) cells were most sensitive to these FMD com-
pounds. Among the FMD compounds, FMD-2Br-DAB and FMD-2I-DAB
exhibited the strongest antitumor effect, with IC50 values of 15–
75 μM, except IC50 = 175 μM for FMD-2Br-DAB on NIH:OVCAR-3
cells. The cell viability results of these cancer cell lines treated by cisplat-
in are shown in Figs. S2A and B, and the corresponding IC50s are also
listed in Table S1. It is particularly interesting to observe that FMDs as
small molecules exhibited a natural selective killing of cancer cells
(Figs. 1A and B, 2A–D). In contrast, cisplatin killed both normal cells
and cancer cells more effectively than FMDs, but it had unfortunately
poor selectivity and therefore severe toxicity (Fig. S2A and B). Note
that for the ovarian cancer NIH:OVCAR-3 cell line that is a well-
established cisplatin-resistant cell line, cisplatin exhibited a high killing
efﬁciency at low doses (≤5 μM) for 72-hr incubation, but a certain frac-
tion of cancer cells survived event at very high drug doses, showing the
drug resistance. This is more obviously shown in Fig. S2B for the 48 hr-
incubation, which shows that about 12% NIH:OVCAR-3 cancer cells sur-
vived from the high-dose cisplatin treatment. Similarly, a certain frac-
tion of A549 cancer cells also exhibited resistance to cisplatin even at
high doses.
3.3. In Vitro DNA DSB Measurements in Cancer Cells
To understand the antitumor activity, we further measured DNA
DSBs in cancer cells treated by FMD-2Br-DAB as an exemplary FMD
compound, using the HCS DNA Damage (γH2AX) Kit (Invitrogen)0 50 100 150 200
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Fig. 2. Cell viability results of various human cancer cells treated by FMD compoundswith vario
cancer (ME-180). B. Breast cancer (MDA-MB-231). C. Lung cancer (A549). D. Cisplatin-resistan(Luo et al., 2012; Lu et al., 2013). Fig. 3 shows the ﬂuorescence images
of ME-180 cancer cells and the yield of DNA DSBs detected by γH2AX
foci with/without the treatment of 0–200 μM FMD for 12 h. It is seen
that the treatment of the FMD induced a signiﬁcant amount of DSBs in
genomic DNA in cervical cancer cells (P b 0.005); an increase by a factor
of 3–5 in DNA DSB yield was observed with the presence of the FMD
compound at ≥50 μM. Note that at higher concentrations ≥100 μM, no
further increases in the counted number of γH2AX foci were obtained,
but this was due to the severe damage to the DNA by the FMD, leading
to DNA fragmentation. It is well-known that DNA DSBs are difﬁcult to
repair and thus potent inducers of apoptosis (cell death).
3.4. In Vitro Apoptosis Measurements by Assays of Activated Caspases and
DNA Fragmentation
We also measured apoptosis-related caspase activation and DNA
fragmentation in human normal cells (MRC-5) and human cervical can-
cer cells (ME-180) treated by cisplatin or FMD-2Br/I-DAB for 48 h, using
a CellEvent™ Caspase-3/7 Green Detection Kit and a standard APO-
BrdU™ TUNEL Assay Kit (both from Invitrogen), respectively (Luo
et al., 2012; Lu et al., 2013). The results are shown in Fig. 4A–P. First,
Fig. 4A–D,M and N show that cisplatin at 5–15 μM induced a signiﬁcant
activation of caspase-3 and -7 inMRC-5 normal cells,whichwas evident
from a signiﬁcant enhancement in green ﬂuorescence, compared with
untreated cells (P b 0.001). In contrast, the FMD compounds induced
negligible caspase activation (apoptosis) in normal cells at concentra-
tions up to 200 μM for FMD-2Br-DAB and 150 μM for FMD-2I-DAB. Sec-
ond, in striking contrast, the results in Fig. 4E–H, and O for cancer cells
show that the treatment of a FMD compound resulted in a signiﬁcant
activation of caspase-3 and -7 in cancer (ME-180) cells (P b 0.001).
Moreover, the FMD compound also caused clear changes on nuclear
morphology, showing condensed nuclei in the treated cancer cells,
which is typical of late-stage apoptosis. Third, a landmark of cellular0 50 100 150 200
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Fig. 3.Measurements of DNA double-strand breaks (DSBs) in human cervical cancer cells (ME-180) treated by FMD-2Br-DAB. The cancer cells were treatedwith various concentrations of
the FMD compound for 12 h, and then imaged by theHCS (γ-H2AX)DNADamageKit (Invitrogen) using ﬂuorescencemicroscopy. The yields of DNADSBs versus compound concentration
were obtained by quantitative analyses of activated γ-H2AX using an Image J software.
548 Q.-B. Lu et al. / EBioMedicine 2 (2015) 544–553self-destruction by apoptosis is also the activation of nucleases that
eventually degrade the nuclear DNA into fragments. Detection of these
fragments is a straightforward and reliable method to quantify apopto-
tic cells. As shown in Fig. 4I–L and P for ME-180 cancer cells, the treat-
ment of the FMD resulted in an enhancement of apoptosis in a dose-
dependent manner. The fraction of BrdU-positive (apoptotic) cells was
increased from 0.5 ± 0.4% for the cancer cells in control (with 0 μM
FMD) to 40.7 ± 2.6% for the cancer cells treated with 150 μM FMD for
48 h. These data clearly show that the FMD compound resulted in
large enhancements in apoptosis of cancer cells but no normal cells.
We therefore conclude that the FMD compound led to DNA damage
and apoptosis preferentially in cancer cells.
3.5. Cell Cycle Analysis of Cancer Cells Using Flow Cytometry
Using the same APO-BrdU™ TUNEL Assay Kit (Invitrogen), we per-
formed cell cycle analysis of human cervical cancer cells (ME-180)
treated by FMD-2Br-DAB at 0 and 100 μM for 48 h. The results are
shown in Fig. 5. The cell cycle histograms contain statistics giving per-
centages for G1, S, and G2 phases of the cycle. It was observed that the
treatment of the 50 μM FMD compound led to a slight decrease in the
percentage of G1 phase from~33% to ~30%, a decrease in the percentage
of G2 phase from ~24% to ~13% and an increase in the percentage of Sphase from ~36% to ~54%. These results show that the FMD agent in-
duced DNA damage and blocked the cells in the DNA synthesis (S
phase) (P b 0.005), in good agreement with the observed DNA damage
caused by the FMD (Fig. 3). These results indicate that the FMD-induced
DNA damage activated cell-cycle checkpoints, which induced a S-phase
arrest. This is consistent with the generally accepted notion that DNA
damage leads to cell cycle arrest; when repair of damage is difﬁcult or
incomplete, the cells undergo apoptosis. Thus, the inducedDNAdamage
is closely associated with activation of cell-cycle checkpoints and
apoptosis.
3.6. Measurements of Reduced Glutathione Levels in Normal and Cancer
Cells Treated by a FMD
Wemeasured the intracellular reduced glutathione (GSH) levels of
both human normal cells (GM05757) and human cervical cancer cells
(ME-180) in control (with no FMDs) and treated by an exemplary
FMD compound (FMD-2Br-DAB) at various concentrations (0, 50, and
100 μM) for 24 h using a GSH detection kit (Abcam), following the
manufacturer's protocol. The results are shown in Fig. 6. It is interesting
to observe that the FMD caused an increase by about 40% of the GSH
level in normal cells at 100 μM FMD. In contrast, the FMD signiﬁcantly
decreased the GSH level in cancer cells, compared with the untreated
Fig. 4.Measurements of apoptosis in humannormal cells (MRC-5) andhuman cervical cancer cells (ME-180) treated by cisplatin or FMD-2Br/I-DAB. The cellswere treated at various agent
concentrations for 48 h, and then analyzed by the CellEvent™ Caspase-3/7 GreenDetection Kit usingﬂuorescencemicroscopy and the APO-BrdUTUNEL Assay Kit using ﬂowcytometry. A–
D: Apoptosis in MRC normal cells with activated caspases represented by green ﬂuorescence. E–H: Apoptosis in ME-180 cancer cells with activated caspases represented by green ﬂuo-
rescence. I–L: TUNEL assay of DNA fragmentation in ME-180 cancer cells; the cells in the right side of the vertical line are BrdU-positive cells (apoptotic cells) with percentages indicated.
M–N: Percentages of MRC normal cells with activated caspases 3/7 versus cisplatin/FMD compound concentration. O–P: Percentages of activated caspases 3/7 and apoptosis (DNA frag-
mentation) in ME-180 cancer cells with versus FMD compound concentration.
Fig. 5.Cell cycle analysis byﬂowcytometry of human cervical cancer cells (ME-180) treated by FMD-2Br-DAB for 48 h. The cell cycle histograms contain statistics givingpercentages for G1,
S, and G2 phases of the cycle, analyzed using a FlowJo software. The ﬁts to the DNA histograms of the samples were performed by theWatsonmodel. A:ME-180 cancer cells in control. B:
ME-180 cancer cells treated by 100 μM FMD. C: Percentages of cell-cycle phases versus FMD concentration.
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Fig. 6. Changes of the reduced glutathione (GSH) in human normal cells and human cervical cancer (ME-180) cells treated by FMD-2Br-DAB for 24h. Both human normal cells (GM05757)
and human cervical cancer cells (ME-180)were treated by FMD-2Br-DAB at various concentrations (0, 50, and 100 μM) for 24 h. The intracellular reduced glutathione (GSH) levels in the
cells were then measured by a GSH detection kit (Abcam). The values were normalized to those of the cells in control.
550 Q.-B. Lu et al. / EBioMedicine 2 (2015) 544–553cells (P b 0.001); theGSH levelwas decreased by about 65% (to ~35%) at
100 μM FMD. The marked selective depletion of the GSH is consistent
with the expected DET reaction between a FMD and a GSH moleculeFig. 7.Mouse xenograft models of human cervical (ME-180) cancer, lung (A549) cancer, breas
For chemotherapy, FMD-2Br-DAB at 7 mg/kg/day or FMD-2I-DAB at 5mg/kg/day was administ
2Br-DABwith totally 5 treatments signiﬁcantly suppressed cervical (ME-180) tumor growth, co
DABwith totally 5 treatments signiﬁcantly suppressed lung (A549) tumor growth, comparedw
ments signiﬁcantly suppressed breast (MDA-MB-231) tumor growth, compared with the cont
treatments signiﬁcantly suppressed cisplatin-resistant ovarian (NIH:OVCAR-3) tumor growth, c
iations in the xenograftmodel of cervical (ME-180) cancer for the control group and the group tr
of lung (A549) cancer for the control group and the groups treated by FMD-2Br-DAB or FMD-2I
OVCAR-3) cancer for the control group and the groups treated by FMD-2Br-DAB or FMD-2I-DAB
group and the treated group on day 40, both in situ and after surgical resection. I. Acute toxicity
rotoxicity (blood urea, creatinine), and electrolytes (Na, K, etc.) were measured from the blo
DAB × 10; 5 mg/kg FMD-2I-DAB × 10), where ALP = lkaline phosphatase, ALT = alanine aminpreferentially in cancer cells. This is also consistent with the observed
selective cytotoxic effects of the FMDs shown in Figs. 1–5 above and
Figs. 7 and 8 below.t (MDA-MB-231) cancer and ovarian (NIH:OVCAR-3) cancer treated by a FMD compound.
rated by IP injection into themice, with totally 5/10 treatments at each other day. A: FMD-
mparedwith the control groupwith no treatment (P b 0.001). B: FMD-2Br-DAB or FMD-2I-
ith the control groupwith no treatment (P b 0.001). C: FMD-2Br-DABwith totally 10 treat-
rol group with no treatment (P b 0.001). D: FMD-2Br-DAB or FMD-2I-DAB with totally 10
omparedwith the control groupwith no treatment (P b 0.001). E:Mouse bodyweight var-
eated by FMD-2Br-DAB (P N 0.05). F:Mouse bodyweight variations in the xenograftmodel
-DAB (P N 0.05). G: Mouse bodyweight variations in the xenograft model of ovarian (NIH:
(P N 0.05). H: Representative pictures of xenograft ME-180 tumors inmice for the control
tests of FMD-2Br-DAB and FMD-2I-DAB inmice: the hepatotoxicity (ALT, ALP, TBIL), neph-
od samples collected from the mice at the end of the 10 treatments (7 mg/kg FMD-2Br-
otransferase, and TBIL = total bilirubin.
Fig. 8.Apoptosismeasurements in lung cancer (A549) xenograftmodel. Tissue sampleswere collected from the tumors grown inmice in the control group and treatment groups (7mg/kg
FMD-2Br-DAB× 5; 5mg/kg FMD-2I-DAB × 5) at 24 h post-treatment and sectioned at 4 μmonto polarized slides. A colorimetric TUNEL assay of the tissue slideswas then performedusing
the DeadEnd™ Colorimetric TUNEL System to visualize and quantify apoptotic cells. The arrows in the images indicate apoptotic cells. A: Tumor tissue frommice in control with no FMD
treatment. B: Tumor tissue from mice treated by FMD-2Br-DAB. C: Tumor tissue from mice treated by FMD-2I-DAB. D: Percentages of apoptotic cells in tumor tissue with various
treatments.
551Q.-B. Lu et al. / EBioMedicine 2 (2015) 544–5533.7. In Vivo Anti-Cancer Effect Tests in Xenograft Mouse Models of Cancers
The in vivo anti-cancer effects of FMD-2Br-DAB and FMD-2I-DAB
were investigated in the xenograft mouse models of human cervical
cancer (ME-180), lung cancer (A549), breast cancer (MDA-MB-231)
and ovarian cancer (NIH:OVCAR-3). It was reported that mice treated
with a daily dose of 2.3 mg/kg cisplatin for 5 days, followed by 5 days
of rest, for two cycles (similar to those used in patients), showed a sig-
niﬁcant decrease in mean body weight compared to vehicle control
after the ﬁrst and second treatment cycle (Ta et al., 2009). Half the
mice treated with a single dose of 15 mg/kg cisplatin alone died within
5 days, while the cisplatin-treated mice sacriﬁced at 5 days had signiﬁ-
cantly elevated levels of blood urea nitrogen (BUN) (Townsend and
Hanigan, 2002). The typical dose of cisplatin for chemotherapy alone
or in combination with another agent or therapy is 2–7.5 mg/kg per
treatment in xenograft mouse tumor models (Lee et al., 2007; Coxon
et al., 2012). For our present experiments, FMD-2Br-DAB and FMD-2I-
DABwere administrated at 7mg/kg/day and 5mg/kg/day, respectively:
totally 5 treatments (days) for ME-180 and A549 models and 10 treat-
ments for MDA-MB-231 and NIH:OVCAR-3 models (given in each
other day). The results are shown in Fig. 7A–I. Fig. 7A–D show that the
FMDs signiﬁcantly suppressed cervical, lung, breast and ovarian tumor
growths, respectively, compared with the control group with no FMD
(P b 0.001). It was also observed in Fig. 7A that the FMD resulted in a sig-
niﬁcant cervical tumor regrowth delay of more than 30 days in vivo.
Fig. 7H shows the pictures of xenograft cervical tumors in mice for the
control group and the treated group on day 40, both in situ and after
surgical resection. Fig. 7B–D also shows that the FMD agents effectivelysuppressed the lung, breast and ovarian tumor growths with the obser-
vations up to 33–51 days. Remarkably, FMD-2I-DAB effectively sup-
pressed the cisplatin-resistant NIH:OVCAR-3 ovarian tumor growth.
These results exhibited a large difference between the control group
and the treated group (P b 0.001), indicative of a high drug efﬁcacy.
3.8. In Vivo Acute Toxicity and Physical Toxicity Measurements in Xenograft
Mouse Models of Cancers
For acute toxicity assay, blood samples were collected by a terminal
cardiac puncture of the mice at the end of the treatment with 0 and
7 mg/kg FMD-2Br-DAB or 5 mg/kg FMD-2I-DAB daily for 10 days. The
acute drug toxicity was assessed throughmeasurements of the hepato-
toxicity (ALT, ALP, total bilirubin), nephrotoxicity (blood urea, creati-
nine), and electrolytes (Na, K, Cl). The overall drug toxicity was
studied through body weight measurements. Fig. 7E, F and G shows
that there were no effects of the FMD compounds on the weight of
mice with time, i.e., the FMD exhibited no physical toxicity. Fig. 7I
shows that the FMDs induced no observable changes in biomarkers of
hepatotoxicity and nephrotoxicity and no changes in electrolytes.
These results indicate that the FMD compounds induced no overall
and acute toxicity (P N 0.05).
3.9. In Vivo Apoptosis Measurements in Lung Cancer Xenograft Model
The in vivo cell death induced by FMD-2Br-DAB at 7 mg/kg × 5 and
FMD-2I-DAB at 5 mg/kg × 5 was investigated in the xenograft mouse
tumor model of human lung cancer (A549). Apoptotic cells in tumor
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shown in Fig. 8, there was a signiﬁcant enhancement in apoptosis in
the tumor tissue treated by the FMD compounds, compared with the
untreated group (P b 0.001). Among the FMD agents, FMD-2I-DAB is
the most effective inducer of apoptosis. These results indicate that
FMDs induced apoptosis in the tumor and are therefore effective anti-
cancer agents.
Overall, the observed in vivo results (Figs. 7 and 8) are consistent
with the in vitro results (Figs. 1-6 and Table S1). The in vitro results
demonstrate that the presence of a FMD compound effectively killed
tumor cells but no normal cells by inducing signiﬁcant DNA DSBs and
apoptosis in cancer cells. This is consistent with the proposed DET
mechanism for the FMD compounds with weakly-bound electrons
that may intrinsically exist in cancer cells. Correspondingly, the in vivo
results in mice conﬁrm that the FMDs indeed generated sufﬁcient
anti-cancer effects while inducing minimal or no toxic side effects.
4. Discussion
Our studies of FMD in cancer have led to the discoveries of a reduc-
tive damaging mechanism in DNA (Wang et al., 2009; Nguyen et al.,
2011) and living cells (Lu et al., 2013) and of themolecularmechanisms
of existing anti-cancer agents (Lu, 2007; Lu et al., 2007; Wang et al.,
2006;Wang and Lu, 2007, 2010). These have offered unique opportuni-
ties to develop neweffective drugs for targeted chemotherapy of cancer.
Our recent results on cell experiments showed that an exogenous anti-
oxidant induced signiﬁcant DNA damage and apoptosis (cell death) in
human normal cells through a reductive mechanism (Lu et al., 2013).
Antioxidants may have a promotion effect in causing cancer (The
ATBC, 1994; Albanes et al., 1996; Omenn et al., 1996; DeNicola et al.,
2011; Lu et al., 2013), and reduce the effect of an exogenous reducing
agent in killing tumor cells (Lu et al., 2013). This is probably because
weakly-bound electrons in antioxidants can cause serious reductive
DNA damage, which if not repaired properly, can lead to apoptosis, ge-
netic mutations and likely diseases notably cancer. Thus, it is reasonable
to speculate that abnormal (cancer) cells may have a more reduced in-
tracellular/intranuclear environment and may therefore have some re-
sistance to an exogenous reducing agent (antioxidant). Our ﬁnding of
a reductive DNA-damaging mechanism might be an important step
for effective prevention and therapy of cancer.
We have now successfully found a previously unknown family of
non-platinum-based anticancer compounds (called FMD compounds)
as potent antitumor agents for natural targeted chemotherapy without
the need of using an antibody to bind to cancer cells. Upon entering nor-
mal and abnormal (cancer) cells, the FMD compounds, which are highly
oxidizing agents, have effects just opposite to those induced by antiox-
idants and are capable of generating the anti-cancer effects on cancer
cells while havingminimal toxicity toward normal cells. They are highly
reactivewithweakly-boundelectrons rich in themore reduced intracel-
lular/intranuclear environment of cancer cells. In contrast, the FMDs are
much less toxic toward normal cells due to the lack of a reduced intra-
cellular/intranuclear environment in normal cells. Therefore FMDs
have no or low systemic or acute toxicity in the body. They are effective
anti-cancer agents that can preferentially kill cancer cells and are there-
fore useful for natural targeted chemotherapy of cancer and potentially
other disorders treatable by chemotherapy. The FMDs are superior to
cisplatin, which has poor target selectivity and is highly toxic due to
the containing of the heavymetal (Pt) readily binding to proteins in kid-
ney (Townsend andHanigan, 2002; Zhang et al., 2006), though cisplatin
has also generally stronger toxicity against cancer cells.
To the best our knowledge, no previous studies showing consider-
able toxicity of our identiﬁed FMD compounds have been reported in
the literature. A previous study by Yu et al. (2008) showed that all six
non-halogenated and halogenated (chlorinated) phenylenediamines
(PD) as dye precursors used tomanufacture hair dyes are not toxic/mu-
tagenic in Salmonella typhimurium TA102 bacteria or skin keratinocytecells, and do not cause DNA cleavage inΦX 174 phage DNA. Their pho-
totoxicity test in skin cells showed that without light irradiation, all the
PD compounds are not toxic to the keratinocytes up to 1000 μM; only at
an extremely high PD concentration (1000 μM) and with extensive ex-
posure to light irradiation (at a large light dose of 3.3 J/cm2 of UVA and
6.3 J/cm2 of visible light), two chlorinated PDs and two non-chlorinated
PDs showmodest phototoxicity. However, the phototoxicity is a subject
that has no direct relevance to the work reported in our present
manuscript.
In the present studies, our in vitro results from cell viability mea-
surements show that the FMD compounds signiﬁcantly enhanced the
killing of both cisplatin-sensitive cancer cells and cisplatin-resistant
cancer cells. Furthermore, large enhancements in DNA damage and ap-
optosis in the treated cancer cells but no normal cells were also ob-
served. Our cell cycle measurements also correspondingly show that
the FMD compounds signiﬁcantly inhibited DNA synthesis in the cell
cycle, resulting in cell arrest in the S phase. We also found that the
FMD compounds exhibited little toxicity toward human normal cells
with measured IC50 values ≥200 μM, in contrast to the clinically
widely-used but highly-toxic cisplatin with IC50s ≤10 μM for 72-hr in-
cubation. Very interestingly, we also observed the marked difference
inmodifying the levels of the reduced glutathione (GSH, an endogenous
antioxidant) in normal and cancer cells. A FMD up to 100 μM caused a
signiﬁcant increase of the GSH level in normal cells, while it largely de-
pleted the GSH in cancer cells. Although further studies as to how the
FMD compound enhances the GSH level in normal cells are needed,
these results indicate a selective strong reaction between the FMD and
theGSHwithin cancer cells and to kill the latter. Thus, these FMD agents
are ideal potent anticancer agents.
Correspondingly, our in vivo results have clearly conﬁrmed that
FMD-2Br-DAB and FMD-2I-DAB as exemplary FMD compounds exhibit-
ed no or minimal toxicity in mice, no overall physical toxicity and no
acute toxicity (no hepatotoxicity, no nephrotoxicity, and no changes
in electrolytes). These results are in excellent agreement with the
in vitro results observed in human normal cells. Furthermore, the
in vivo results from the xenograft mouse tumormodels of human cervi-
cal cancer, lung cancer, breast cancer and ovarian cancer exhibited sig-
niﬁcant tumor growth inhibition and regrowth delay due to the anti-
cancer effect of the FMD compounds. These results demonstrate that
the FMDs are indeed potent anti-cancer agents for natural targeted che-
motherapy. Given that only a small dose (5 or 7 mg/kg) of the FMDs
were used in the present experiment and that the FMDs showed little
or no toxicity at much higher doses in vitro, it is reasonably expected
that these results can be extrapolated to larger doses or more frequent
treatments so that a maximal therapeutic efﬁcacy can be achieved.
Finally, it is expected that our in vitro and in vivo results obtained in
this study may be applied to other cancer types and models beyond
those exempliﬁed here. This innovative study in FMD represents an ef-
ﬁcient and economical rational approach for discovery of novel antican-
cer agents, which is superior to the screening strategy of a large library
of compounds. Discovered on a well-established DET mechanism of ac-
tion, these FMD compounds being essentially non-toxic, small mole-
cules and therefore readily for delivery to cancer sites should have
large opportunities for success in clinical trials and ultimate use in can-
cer patients in the clinic. The present study also demonstrates the great
potential of FMD as a new frontier in biomedical research to bring
breakthroughs in fundamental understandings of major human dis-
eases such as cancer and ultimately in therapies of diseases in clinical
settings.
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